EZH2 and myeloproliferative disorder: Also Agarwal et al., using a customized 26-gene NGS panel in a series of 171 MPN patients, highlighted that alterations in ASXL1, EZH2, and IDH1/2 were associated with an increasing risk of disease progression and a shorter OS in both ET and PMF patients.